5-chloro-3-(4-methanesulfonylphenyl)-6' -methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis

Details for Australian Patent Application No. 2001292907 (hide)

Owner Merck & Co., Inc.

Inventors Kotliar, Andrew; Davies, Ian W.; Osifchin, Richard G.; Crocker, Louis S.

Agent Spruson & Ferguson

Pub. Number AU-B-2001292907

PCT Pub. Number WO2002/096877

Priority 09/865,771 25.05.01 US

Filing date 21 September 2001

Wipo publication date 9 December 2002

Acceptance publication date 26 July 2007

International Classifications

C07D 213/61 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/444 (2006.01)

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

8 May 2003 Application Open to Public Inspection

  Published as AU-B-2001292907

26 July 2007 Application Accepted

  Published as AU-B-2001292907

22 November 2007 Standard Patent Sealed

21 January 2010 Amendment Made

  The nature of the amendment is: Amend the patentee name from Merck & Co., Inc. to Merck Sharp & Dohme Corp. 2002

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001292908

2001292906-Characterization of the GSK-3beta protein and methods of use thereof